---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-000885"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:16:49.359263+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports Q4 sales down 1.6% YoY; records $3.6M impairment, pauses Re-Tain

## Summary
- Q4 total sales $7.6M (-1.6% YoY); domestic sales up 8.7%, international down 52.6%.
- FY 2025 total sales $27.6M (+4.3% YoY); Tri-Shield sales $19.9M (+26.5%), Dual-Force $6.9M (-27.4%).
- Records $3.6M non-cash impairment: $2.9M Re-Tain PPE, $0.1M other PPE, $0.6M colostrum inventory write-down.
- Pausing Re-Tain investment after FDA Incomplete Letter; repurposing $15.5M Re-Tain assets for First Defense.
- Tri-Shield sales exceed expectations; expanding sales force by 50% with new U.S. territories and international hire.

## SEC filing metadata
- accession: 0001437749-26-000885
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.06, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/0001437749-26-000885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/iccc20260108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-000885
- JSON: https://secwatch.observer/filing/0001437749-26-000885.json
- Plain text: https://secwatch.observer/filing/0001437749-26-000885.txt

## Source-grounded claims
- claim_id: 437d6b9aecfcd125e950a010726fa6401a3ebb8e
  claim: IMMUCELL CORP /DE/ announced a impairment with charges of approximately $2.9 million affecting Re-Tain®.
  evidence_excerpt: The resulting non-cash impairment write-down of property, plant and equipment pertaining to Re-Tain® is currently estimated at approximately $2.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/0001437749-26-000885-index.htm
- claim_id: 5447c58031acd707dd574af83ac368f5e16e1c99
  claim: IMMUCELL CORP /DE/ announced a impairment with charges of $0.6 million write-down affecting work-in-process colostrum inventory.
  evidence_excerpt: a $0.6 million write-down primarily of work-in-process colostrum inventory that was determined to no longer be fit for processing into First Defense®
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/0001437749-26-000885-index.htm
- claim_id: ca3f1c4fc0093bd2114f0ee8ac3dc0857fc33e7b
  claim: IMMUCELL CORP /DE/ announced a impairment with charges of approximately $3.6 million in non-cash impairment write-downs affecting Re-Tain® assets and other property, plant and equipment and inventory.
  evidence_excerpt: the Company announced that it will record approximately $3.6 million in non-cash impairment write-downs during the three-month period ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/0001437749-26-000885-index.htm
- claim_id: e2e7bff3c07df648c096485f749a48dca59f8808
  claim: IMMUCELL CORP /DE/ announced a impairment with charges of $0.1 million, non-cash impairment write-down affecting certain property, plant and equipment, unrelated to Re-Tain®.
  evidence_excerpt: the Company has identified a $0.1 million, non-cash impairment write-down of certain property, plant and equipment
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/0001437749-26-000885-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.